ORXOF (Orexo AB) SpecialCharges


ORXOF Orexo AB ORXOF
34 GF Score
Price $2.10
GF Value $0.68
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Orexo AB SpecialCharges?

Special Charges only applies to banks.

ORXOF
34GF Score
Orexo AB ORXOF
SpecialCharges is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Orexo AB (ORXOF) Overvalued in 2026?

Based on GuruFocus' analysis, Orexo AB stock appears to be overvalued. The current stock price of $2.10 is trading 208.8% above its estimated GF Value™ of $0.68. GuruFocus considers Orexo AB to be Significantly Overvalued.

Key valuation signals for ORXOF:

  • SpecialCharges:
  • GF Value™: $0.68 vs. price of $2.10 (208.8% above fair value)
  • GF Score™: 34/100 with 7 warning signs

No single metric tells the full story. See the ORXOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Orexo AB Business Description

Address Virdings alle 22, Uppsala, SWE, 75105
Orexo AB is a Swedish pharmaceutical company dedicated to advancing treatments for severe diseases and life-saving rescue medications to meet future healthcare needs, developing improved medications based on proprietary drug delivery technologies. At the core of its innovation is AmorphOX, which improves bioavailability and stability for both large and small molecules. It has developed four drugs from concept to approval, including Zubsolv, Abstral, Edluar, and Diabact UBT. The company's current development efforts focus on AmorphOX, with projects in preclinical and clinical phases across multiple therapeutic areas. It operates through US Commercial and HQ & Pipeline, which generate maximum revenue, and operates in the US, EU, and UK generating maximum revenue, and the Rest of the World.
34GF Score

Get the complete analysis for ORXOF

SpecialCharges is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.10
Price
$0.68
GF Value